cyc 202 has been researched along with belinostat in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (belinostat) | Trials (belinostat) | Recent Studies (post-2010) (belinostat) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 208 | 30 | 167 |
| 979 | 7 | 393 | 8 | 0 | 7 |
| Protein | Taxonomy | cyc 202 (IC50) | belinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.1942 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.027 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.2147 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.1602 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 5.12 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.816 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2401 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.5966 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.2526 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.1946 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.0357 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2147 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chia, DM; Chinnathambi, A; Goh, BC; Ho, PC; Kong, LR; Lau, JY; Ong, PS; Seah, JY; Sethi, G; Thuya, WL; Wang, L; Wong, AL; Yang, D; Yong, WP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
2 other study(ies) available for cyc 202 and belinostat
| Article | Year |
|---|---|
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Caspase Inhibitors; Cell Proliferation; Dose-Response Relationship, Drug; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Purines; RNA Interference; Roscovitine; Signal Transduction; Sulfonamides; Time Factors; Transfection; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein | 2016 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |